{"id":"https://openalex.org/W7225112893","doi":"https://doi.org/10.5281/zenodo.23897527","title":"Writing and Amending the Clinical Protocol: IND and CTA Lifecycle Strategy for Oral GLP-1 Receptor Agonists in Type 2 Diabetes and Obesity","display_name":"Writing and Amending the Clinical Protocol: IND and CTA Lifecycle Strategy for Oral GLP-1 Receptor Agonists in Type 2 Diabetes and Obesity","publication_year":2026,"publication_date":"2026-11-02","ids":{"openalex":"https://openalex.org/W7225112893","doi":"https://doi.org/10.5281/zenodo.23897527"},"language":"en","primary_location":{"id":"doi:10.5281/zenodo.23897527","doi":"https://doi.org/10.5281/zenodo.23897527","is_oa":true,"landing_page_url":"https://doi.org/10.5281/zenodo.23897527","pdf_url":null,"source":{"id":"https://openalex.org/S4306400562","display_name":"Zenodo (CERN European Organization for Nuclear Research)","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I67311998","host_organization_name":"European Organization for Nuclear Research","host_organization_lineage":["https://openalex.org/I67311998"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article-journal"},"volume":null,"type":"article","indexed_in":["datacite"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://doi.org/10.5281/zenodo.23897527","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5157910184","display_name":"Riddhi Rohan Moradiya","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Moradiya, Riddhi Rohan","raw_affiliation_strings":["Northeastern University, Toronto"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Northeastern University, Toronto","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5157915278","display_name":"Aditi Shivakumar Hipparagi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shivakumar Hipparagi, Aditi","raw_affiliation_strings":["Northeastern University, Toronto"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Northeastern University, Toronto","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5128207978","display_name":"Peivand Pirouzi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I61412661","display_name":"Seneca Polytechnic","ror":"https://ror.org/04qgh9k98","country_code":"CA","type":"education","lineage":["https://openalex.org/I61412661"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Pirouzi, Peivand","raw_affiliation_strings":["College of Professional Studies, Northeastern University, Toronto, ON, Canada","School of Health Sciences, Seneca Polytechnic, Toronto, ON, Canada","Crown College of Canada, Toronto, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"College of Professional Studies, Northeastern University, Toronto, ON, Canada","institution_ids":[]},{"raw_affiliation_string":"School of Health Sciences, Seneca Polytechnic, Toronto, ON, Canada","institution_ids":["https://openalex.org/I61412661"]},{"raw_affiliation_string":"Crown College of Canada, Toronto, ON, Canada","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.87459064,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9937000274658203,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9937000274658203,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.0020000000949949026,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.0012000000569969416,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/oral-glp-1-receptor-agonists","display_name":"oral GLP-1 receptor agonists","score":1.0},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9750000238418579},{"id":"https://openalex.org/keywords/obesity","display_name":"obesity","score":1.0},{"id":"https://openalex.org/keywords/investigational-new-drug-application","display_name":"Investigational New Drug application","score":0.8809999823570251},{"id":"https://openalex.org/keywords/clinical-trial-applications","display_name":"clinical trial applications","score":0.9309999942779541},{"id":"https://openalex.org/keywords/protocol-amendments","display_name":"protocol modification","score":0.7490000128746033},{"id":"https://openalex.org/keywords/regulatory-affairs","display_name":"regulatory affairs","score":0.5860000252723694},{"id":"https://openalex.org/keywords/clinical-trial-management","display_name":"clinical trial management","score":0.6060000061988831},{"id":"https://openalex.org/keywords/gastrointestinal-tolerability","display_name":"gastrointestinal tolerance","score":0.8669999837875366},{"id":"https://openalex.org/keywords/dose-titration","display_name":"dose titration","score":0.843999981880188},{"id":"https://openalex.org/keywords/pharmacovigilance","display_name":"pharmacovigilance","score":0.9440000057220459},{"id":"https://openalex.org/keywords/fda-regulation","display_name":"FDA regulation","score":0.5529999732971191}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7836999893188477},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.6348999738693237},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.47850000858306885},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4763999879360199},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.4381999969482422},{"id":"https://openalex.org/C2778176773","wikidata":"https://www.wikidata.org/wiki/Q2976049","display_name":"Drug class","level":3,"score":0.4332999885082245},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.4235000014305115},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4056999981403351},{"id":"https://openalex.org/C57658597","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Pharmacovigilance","level":3,"score":0.35429999232292175},{"id":"https://openalex.org/C2780385302","wikidata":"https://www.wikidata.org/wiki/Q367158","display_name":"Protocol (science)","level":3,"score":0.3458999991416931},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.3424000144004822},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.32989999651908875},{"id":"https://openalex.org/C4438859","wikidata":"https://www.wikidata.org/wiki/Q186117","display_name":"Timeline","level":2,"score":0.3287999927997589},{"id":"https://openalex.org/C64903051","wikidata":"https://www.wikidata.org/wiki/Q2198549","display_name":"Drug development","level":3,"score":0.32589998841285706},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.29339998960494995},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.28929999470710754}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.5281/zenodo.23897527","doi":"https://doi.org/10.5281/zenodo.23897527","is_oa":true,"landing_page_url":"https://doi.org/10.5281/zenodo.23897527","pdf_url":null,"source":{"id":"https://openalex.org/S4306400562","display_name":"Zenodo (CERN European Organization for Nuclear Research)","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I67311998","host_organization_name":"European Organization for Nuclear Research","host_organization_lineage":["https://openalex.org/I67311998"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article-journal"},{"id":"doi:10.5281/zenodo.23897528","doi":"https://doi.org/10.5281/zenodo.23897528","is_oa":true,"landing_page_url":"https://doi.org/10.5281/zenodo.23897528","pdf_url":null,"source":{"id":"https://openalex.org/S4306400562","display_name":"Zenodo (CERN European Organization for Nuclear Research)","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I67311998","host_organization_name":"European Organization for Nuclear Research","host_organization_lineage":["https://openalex.org/I67311998"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article-journal"}],"best_oa_location":{"id":"doi:10.5281/zenodo.23897527","doi":"https://doi.org/10.5281/zenodo.23897527","is_oa":true,"landing_page_url":"https://doi.org/10.5281/zenodo.23897527","pdf_url":null,"source":{"id":"https://openalex.org/S4306400562","display_name":"Zenodo (CERN European Organization for Nuclear Research)","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I67311998","host_organization_name":"European Organization for Nuclear Research","host_organization_lineage":["https://openalex.org/I67311998"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article-journal"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7222867757","https://openalex.org/W7168040099","https://openalex.org/W7168179046","https://openalex.org/W7220686887","https://openalex.org/W7154685041","https://openalex.org/W7116073760","https://openalex.org/W7128697474","https://openalex.org/W7125386705","https://openalex.org/W7212246826","https://openalex.org/W2508533215"],"abstract_inverted_index":{"Glucagon-like":[0],"peptide-1":[1],"(GLP-1)":[2],"receptor":[3,46,90,208],"agonists":[4],"have":[5],"transformed":[6],"the":[7,62,71,79,112,124,150,157,179],"management":[8],"of":[9,37,65,81,172,181],"type":[10,210],"2":[11,211],"diabetes":[12,126],"and":[13,31,55,120,127,132,140,154,160,166,178,188,198],"obesity,":[14],"but":[15],"existing":[16],"approved":[17],"agents":[18],"in":[19],"this":[20,66,203],"class":[21,68],"are":[22],"administered":[23],"by":[24],"subcutaneous":[25],"injection,":[26],"a":[27,34,82,169,175],"barrier":[28],"to":[29,60,137,185],"initiation":[30],"adherence":[32],"for":[33,117,195],"meaningful":[35],"proportion":[36],"eligible":[38],"patients":[39],"(Davies":[40],"et":[41],"al.,":[42],"2022).":[43],"Oral":[44],"GLP-1":[45,89,207],"agonists,":[47],"including":[48],"both":[49],"peptide":[50],"formulations":[51],"using":[52],"absorption-enhancing":[53],"excipients":[54],"non-peptide":[56],"small":[57],"molecules,":[58],"aim":[59],"retain":[61],"metabolic":[63],"benefit":[64],"drug":[67],"while":[69],"removing":[70],"injection":[72],"barrier.":[73],"This":[74],"article":[75,191],"is":[76],"written":[77],"from":[78,93,147],"perspective":[80],"clinical":[83,199],"trial":[84,118],"manager":[85],"carrying":[86],"an":[87],"oral":[88,206],"agonist":[91],"program":[92],"its":[94],"initial":[95,158],"Investigational":[96,216],"New":[97,217],"Drug":[98,218],"(IND)":[99],"application":[100,180],"or":[101],"Clinical":[102,220],"Trial":[103,221],"Application":[104],"(CTA)":[105],"through":[106],"subsequent":[107],"protocol":[108,214],"amendments.":[109],"It":[110],"reviews":[111],"pharmacological":[113],"rationale,":[114],"best":[115],"practices":[116],"phase":[119],"population":[121],"selection":[122],"across":[123,162],"overlapping":[125],"obesity":[128],"indications,":[129],"anticipated":[130],"risks":[131],"pharmacovigilance":[133],"strategy":[134],"with":[135,193],"attention":[136],"gastrointestinal":[138,223],"tolerability":[139],"dose":[141],"titration,":[142],"statistical":[143],"sample-size":[144],"rationale":[145],"drawn":[146],"registered":[148],"trials,":[149],"detailed":[151],"regulatory":[152,196,225],"requirements":[153],"timelines":[155],"governing":[156],"submission":[159],"amendments":[161],"FDA,":[163],"Health":[164],"Canada,":[165],"EMA":[167],"frameworks,":[168],"representative":[170],"schedule":[171],"assessments":[173],"spanning":[174],"twelve-month":[176],"period,":[177],"artificial":[182,226],"intelligence":[183,227],"tools":[184],"data":[186],"capture":[187],"quality.":[189],"The":[190],"closes":[192],"recommendations":[194],"affairs":[197],"operations":[200],"professionals":[201],"managing":[202],"therapeutic":[204],"category.Keywords:":[205],"agonist;":[209],"diabetes;":[212],"obesity;":[213],"amendment;":[215],"application;":[219],"Application;":[222],"tolerability;":[224]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2026-11-03T00:00:00"}